The European Union approved the single-shot Johnson & Johnson coronavirus vaccine on Thursday—the fourth jab to get the green light for the 27-nation bloc. The…
Read More
FDA Approves Fotivda
FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma BOSTON–(BUSINESS WIRE) March 10, 2021 — AVEO…
Read More
FDA Approves Pepaxto
FDA Approves Pepaxto (melphalan flufenamide) for Patients with Relapsed or Refractory Multiple Myeloma STOCKHOLM, Feb. 26, 2021 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO),…
Read More
FDA Approves Emergency Use of Pfizer’s COVID Vaccine
SATURDAY, Dec. 12, 2020 – The U.S. Food and Drug Administration approved Pfizer’s coronavirus vaccine for emergency use on Friday, clearing the way for the…
Read More
FDA Approves Sklice (ivermectin) Lotion for Nonprescription Use to Treat Head Lice
October 27, 2020 — Today, the U.S. Food and Drug Administration approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through…
Read More
FDA Approves Trijardy XR
FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ — The U.S. Food and Drug…
Read More
FDA Approves Monoferric
FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia MORRISTOWN, N.J., Jan. 29, 2020 /PRNewswire/ — Pharmacosmos Therapeutics Inc. is pleased to announce…
Read More
FDA approves ruzurgi for children with rare autoimmune disorder
(HealthDay)—Ruzurgi (amifampridine) tablets are now approved to treat Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to 17 years, the U.S. Food and Drug Administration…
Read More
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA — March 18, 2019 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the…
Read More
FDA Approves Generic Latuda for Schizophrenia and Bipolar Depression
The cash price for a 30-day supply of brand-name Latuda is around $1,500. Lurasidone’s release could be a reprieve for patients struggling to afford Latuda….
Read More